Company intelligence / Profile preview

Veradermics

New Haven, Connecticut, United Statesveradermics.com ↗

Ownership: Public · MANE
Development stage: Phase 2

Overview

Veradermics has initiated a pivotal Phase 2/3 clinical trial for VDPHL01 for androgenetic alopecia (pattern hair loss). The company plans to report topline data from Phase 2 studies of VDPHL01 in the first half of 2025. They have also dosed the first patient in a Phase 2 clinical trial for VDMN, an immunostimulatory dissolvable microarray patch containing Candida Antigen Extract for common warts treatment[3][5].

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Oral medicationsdissolvable microarray patchantiviral therapeutics
Industry: Biotech

Drug pipeline

2 assets

VDPHL01

1 more asset in the full pipeline.

Request access →

Financials

Market cap: $4.3B
Total revenue: $0
Enterprise value: $3.5B

Beyond the preview

Go deeper on Veradermics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Veradermics.

Explore the full profile